Myeloperoxidase (MPO) is an important component of the
human innate
immune system and the main source of a strong oxidizing and chlorinating
species, hypochlorous acid (HOCl). Inadvertent, misplaced, or excessive
generation of HOCl by MPO is associated with multiple human inflammatory
diseases. Therefore, there is a considerable interest in the development
of MPO inhibitors. Here, we report the synthesis and characterization
of a boronobenzyl derivative of acetaminophen (AMBB), which can function
as a proinhibitor of MPO and release acetaminophen, the inhibitor
of chlorination cycle of MPO, in the presence of inflammatory oxidants,
i.e., hydrogen peroxide, hypochlorous acid, or peroxynitrite. We demonstrate
that the AMBB proinhibitor undergoes conversion to acetaminophen by
all three oxidants, with the involvement of the primary phenolic product
intermediate, with relatively long half-life at pH 7.4. The determined
rate constants of the reaction of the AMBB proinhibitor with hydrogen
peroxide, hypochlorous acid, or peroxynitrite are equal to 1.67, 1.6
× 104, and 1.0 × 106 M–1 s–1, respectively. AMBB showed lower MPO inhibitory
activity (IC50 > 0.3 mM) than acetaminophen (IC50 = 0.14 mM) toward MPO-dependent HOCl generation. Finally,
based
on the determined reaction kinetics and the observed inhibitory effects
of two plasma components, uric acid and albumin, on the extent of
AMBB oxidation by ONOO– and HOCl, we conclude that
ONOO– is the most likely potential activator of
AMBB in human plasma.